

**Online supplementary Table S2: Bacteriological response of the 98 patients treated with multidrug-resistant tuberculosis therapy over 2 years (expanded version)**

Characteristics	Treatment duration (months) (%)												Nonconverter (%)	
	1	2	3	4	5	6	7	8	9	12	15	18		21
Lost to follow-up	0 (0.0)	1 (1.1)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.1)	1 (1.1)	0 (0.0)	1 (1.1)	0 (0.0)	1 (1.1)	0 (0.0)	2 (2.1)	0 (0.0)
Expired Patient	2 (2.1)	1 (1.1)	2 (2.1)	1 (1.1)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.1)	0 (0.0)	0 (0.0)	3 (3.1)	0 (0.0)	0 (0.0)	0 (0.0)
continuing on treatment	96 (97.9)	94 (95.9)	92 (93.8)	91 (92.9)	91 (92.9)	90 (91.8)	89 (90.8)	88 (89.8)	87 (88.8)	87 (88.8)	83 (84.7)	83 (84.7)	81 (82.6)	81 (82.6)
Smear conversion rate	1/96 (1.1)	2/94 (2.1)	28/92 (30.4)	63/91 (69.2)	75/91 (82.4)	80/90 (88.9)	79/89 (88.7)	80/88 (90.9)	79/87 (90.8)	81/87 (93.1)	78/83 (93.9)	77/83 (92.8)	75/81 (92.6)	75/81 (92.6)
Best scenario	1/98 (1.1)	2/98 (2.2)	28/98 (28.6)	63/98 (64.3)	75/98 (76.5)	80/98 (81.6)	79/98 (80.6)	80/98 (81.6)	79/98 (80.6)	81/98 (82.7)	78/98 (79.6)	77/98 (78.6)	75/98 (76.5)	75/98 (76.5)
Worst scenario	95 (96.9)	92 (93.8)	64 (65.3)	28 (28.6)	16 (16.3)	10 (10.2)	10 (10.2)	8 (8.2)	8 (8.2)	6 (6.1)	5 (5.1)	6 (6.1)	6 (6.1)	6 (6.1)
Patient still smear positive	0/96 (0.0)	1/94 (1.1)	26/92 (28.3)	61/91 (67.1)	73/91 (80.2)	75/90 (83.3)	73/89 (82.1)	76/88 (86.4)	77/87 (88.5)	78/87 (89.7)	75/83 (90.4)	74/83 (89.2)	71/81 (87.7)	71/81 (87.7)
Culture conversion rate	0/98 (0.0)	1/98 (1.1)	26/98 (26.5)	61/98 (62.3)	73/98 (74.5)	75/98 (76.5)	73/98 (74.5)	76/98 (77.6)	77/98 (78.6)	78/98 (79.6)	75/98 (76.5)	74/98 (75.5)	71/98 (72.4)	71/98 (72.4)
Best scenario	96 (97.9)	93 (94.8)	66 (67.3)	30 (30.6)	18 (18.4)	15 (15.3)	16 (16.3)	12 (12.3)	10 (10.2)	9 (9.2)	8 (8.2)	9 (9.2)	10 (10.2)	10 (10.2)
Worst scenario	0/96 (0.0)	1/94 (1.1)	26/92 (28.3)	61/91 (67.1)	73/91 (80.2)	75/90 (83.3)	73/89 (82.1)	76/88 (86.4)	77/87 (88.5)	78/87 (89.7)	75/83 (90.4)	74/83 (89.2)	71/81 (87.7)	71/81 (87.7)
Patient still culture positive	0/98 (0.0)	1/98 (1.1)	26/98 (26.5)	61/98 (62.3)	73/98 (74.5)	75/98 (76.5)	73/98 (74.5)	76/98 (77.6)	77/98 (78.6)	78/98 (79.6)	75/98 (76.5)	74/98 (75.5)	71/98 (72.4)	71/98 (72.4)
Best scenario	96 (97.9)	93 (94.8)	66 (67.3)	30 (30.6)	18 (18.4)	15 (15.3)	16 (16.3)	12 (12.3)	10 (10.2)	9 (9.2)	8 (8.2)	9 (9.2)	10 (10.2)	10 (10.2)
Worst scenario	0/96 (0.0)	1/94 (1.1)	26/92 (28.3)	61/91 (67.1)	73/91 (80.2)	75/90 (83.3)	73/89 (82.1)	76/88 (86.4)	77/87 (88.5)	78/87 (89.7)	75/83 (90.4)	74/83 (89.2)	71/81 (87.7)	71/81 (87.7)
Patient still culture positive	0/98 (0.0)	1/98 (1.1)	26/98 (26.5)	61/98 (62.3)	73/98 (74.5)	75/98 (76.5)	73/98 (74.5)	76/98 (77.6)	77/98 (78.6)	78/98 (79.6)	75/98 (76.5)	74/98 (75.5)	71/98 (72.4)	71/98 (72.4)
Best scenario	96 (97.9)	93 (94.8)	66 (67.3)	30 (30.6)	18 (18.4)	15 (15.3)	16 (16.3)	12 (12.3)	10 (10.2)	9 (9.2)	8 (8.2)	9 (9.2)	10 (10.2)	10 (10.2)
Worst scenario	0/96 (0.0)	1/94 (1.1)	26/92 (28.3)	61/91 (67.1)	73/91 (80.2)	75/90 (83.3)	73/89 (82.1)	76/88 (86.4)	77/87 (88.5)	78/87 (89.7)	75/83 (90.4)	74/83 (89.2)	71/81 (87.7)	71/81 (87.7)
Patient still culture positive	0/98 (0.0)	1/98 (1.1)	26/98 (26.5)	61/98 (62.3)	73/98 (74.5)	75/98 (76.5)	73/98 (74.5)	76/98 (77.6)	77/98 (78.6)	78/98 (79.6)	75/98 (76.5)	74/98 (75.5)	71/98 (72.4)	71/98 (72.4)

The analysis performed by the subcommittee has been combined in addition to that of modified DOTS-Plus strategy. DOTS: Directly Observed Treatment Short-Course